You searched for "outpatient"
New senior appointments at The Urology Foundation
New Chief Executive appointed The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and...Management of calyceal diverticular stones using ultramini PCNL
Calyceal diverticulae are congenital smooth-walled, non-secretory urothelium-lined cavities within the renal parenchyma that communicate with calyceal fornix through a diverticular neck. They were first described by Rayer in Traitements des maladies des reins [1]. Calculi occur in approximately 9.5% to...Imaging and surveillance in sporadic renal angiomyolipoma: how and when to monitor effectively
Renal angiomyolipoma (AML) are benign tumours, accounting for approximately 2–3% of all renal neoplasms [1]. Seventy percent of renal AMLs are sporadic, and 20–30% are associated with genetic aetiology. They are composed of smooth muscle, blood vessels, and adipose tissue....
SUSPEND suspended MET
This review is on the recent groundbreaking evidence on medical expulsive therapy (MET). MET using alpha adrenergic blockers (like tamsulosin) are in regular clinical practice. Even though it is an off label prescription, it is well accepted and practised world...Innovative catheter receives “bacteria-phobic™” claim approval from notified body: positive evaluation affirms device resistance to bacterial colonisation
Camstent Ltd’s coated catheter, which has been developed to limit attachment of bacteria to its surfaces, a known source of Catheter Acquired Urinary Tract Infection (CAUTI), has been awarded approval...Action Bladder Cancer UK launches learning module for primary care
Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...
Anti-VEGF and PD-1 combinations in renal cell carcinoma
Over the past decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been central to treating renal cell carcinoma (RCC), with oncologists refining dosing strategies to balance treatment efficacy with quality of life (QoL). Recently, the introduction of...
Defining adjuvant, consolidative, and salvage treatment after RP
The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...
